share_log
Breakings ·  Sep 9 20:01
Reviva Pharmaceuticals Holdings, Inc.: Additional Vocal Biomarker Data From Ongoing Open Label Extension Study Expected Q4 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment